The European Medicines Agency advised its member state regulatory partners to closely track how they use LLMs in making regulatory decisions – a clear signal that some regulatory decisions may be inappropriately torqued by their well-known shortcomings.

Asia Pacific is the fastest growing region for health care spending, and by 2030 APAC will account for more than 20% of global health care spending, Tom Lawry, managing director of Second Century Tech told the APACMed Forum 2024 conference held in Singapore, Sept 5-6.

Asia Pacific is the fastest growing region for health care spending, and by 2030 APAC will account for more than 20% of global health care spending, Tom Lawry, managing director of Second Century Tech told the APACMed Forum 2024 conference held in Singapore, Sept 5-6.

A decade ago, when Asia Pacific Medical Technology Chairman (APACMed) John Collings was running a medtech business in China, he was flying high with multiple rounds of investment under his belt and preparing to launch two new technologies, but the company hit a regulatory hurdle that delayed the launch and he found himself grappling for answers, he told the APACMed Forum held Sept. 5 in Singapore.

Product liability is always a point of concern for manufacturers of medical devices and other U.S. FDA-regulated products, and the broad contours of product liability jurisprudence are well known by corporate counsel. However, artificial intelligence products are rapidly pressing their way into routine clinical use, representing a technological shift that may occasionally deviate from the existing rules of the road where product liability is concerned.

Researchers from Case Western Reserve University and the U.S. Department of Veterans Affairs, continue their development of a neuroprosthetic which comprises a system of implanted or wearable sensors.

The U.K. Medicines and Health Care Products Regulatory Agency enacted its AI Airlock program for artificial intelligence – the agency’s branding for its regulatory sandbox for this type of medical software.

IGC Pharma Inc. has used its artificial intelligence (AI) modeling to identify the company’s proprietary molecule, IGC-1A, as a potential GLP-1 agonist. The company’s AI model compared IGC-1A and IGC-1C to established drugs such as Ozempic (semaglutide), tirzepatide, retatrutide and metformin, among others, and indicated that they could become effective options for metabolic disorders.

The $180 million Caresyntax GmbH recently raised in a series C extension round allows the company to accelerate the commercialization and adoption of its precision surgery platform, Bjorn von Siemens, CFO and CBO of Caresyntax told BioWorld.